MedTrace Logo

Jordan Diabetes Microclinic Project

NCT01596244 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2400

Last updated 2012-11-08

No results posted yet for this study

Summary

The purpose of the study is to provide participants in economically depressed areas of Jordan essential knowledge, practical skills, and intimate support groups-called microclinics-for managing their diabetes. Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular micro-clinic meetings.

Conditions

  • Diabetes Mellitus, Type II

Interventions

BEHAVIORAL

Microclinic

Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.

Sponsors & Collaborators

  • Ministry of Health Jordan

    collaborator OTHER_GOV

  • Royal Health Awareness Society (RHAS), Jordan

    collaborator UNKNOWN

  • Microclinic International

    lead OTHER

Principal Investigators

  • Daniel Zoughbie, DPhil · Microclinic International

  • Eric Ding, PhD · Harvard University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-04-30
Completion
2012-08-31

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01596244 on ClinicalTrials.gov